The Avicenna Alliance itself has its origins in the Avicenna Roadmap, a 2-year EU funded project, led by DG Connect whose goal was to create a research and technological development Roadmap outlining a strategy for in silico Clinical Trials (ISCT).
Built into the European Commission’s project requirements was a plan to establish a pre-competitive Association – the Avicenna Alliance, that would represent the needs of the in silico medicine community and provide the Commission and other policy makers with expert advice in this field.
The Avicenna Alliance operating since 2016, now works with members to implement this Roadmap and identify policy and regulatory obstacles to the enhancement of in silico medicine.
The Avicenna Alliance is a researcher and industry partnership with 50% membership of the Virtual Physiological Human Initiative (VPH) and 50% representation of the medical devices, pharmaceuticals, software and cosmetics industries.
By engaging both researchers and industry in the conversation on how to roll out this roadmap, the Avicenna Alliance is the one stop shop for all things in silico medicine at EU level.
To find out if you could benefit from Membership of the Avicenna Alliance, click here.